

07.11.2019

14:00 - 17:00 Molecular pathology and single cell analysis: New technologies coming to practise **Abbey room**

Moderation: J. Haanen¹, F. André², C. Swanton³, ¹Medical Oncology Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²Breast Cancer Unit, Medical Oncology Department, Gustave Roussy - Cancer Campus, Villejuif, FR, ³Translational Cancer Therapeutics Department, The Francis Crick Institute, London, GB

14:00 - 14:00 **Session DOI**

14:00 - 14:30 **Digital pathology: Emerging technologies in the field**

J. Adam, Institut Gustave Roussy, Villejuif, FR

14:30 - 15:00 **How to analyse data from digital pathology**

T. Graham, Barts Cancer Institute-Queen Mary University of London, London, GB

15:00 - 15:30 **Mass cytometry: Principles and applications**

S. Tietscher, UZH - University of Zurich - Irchel Campus, Zurich, CH

15:30 - 16:00 **Coffee break**

16:00 - 16:30 **Basics of single cell sequencing**

F. Ginhoux, A*STAR - Singapore Immunology Network (SIgN), Singapore, SG

16:30 - 17:00 **Bioinformatics and mathematics to analyse single cell data**

C. Ng, University of Bern, Bern, CH

08.11.2019

08:40 - 08:50 Welcome from the Chairs

Fleming room

Moderation: C. Swanton¹, J. Haanen², F. André³, ¹Translational Cancer Therapeutics Department, The Francis Crick Institute, London, GB, ²Medical Oncology Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ³Breast Cancer Unit, Medical Oncology Department, Gustave Roussy - Cancer Campus, Villejuif, FR

08:40 - 08:50 Welcome to MAP 2019

C. Swanton, The Francis Crick Institute, London, GB

08:50 - 10:30 Molecular target/Disease orientation

Fleming room

Moderation: F. André, Breast Cancer Unit, Medical Oncology Department, Gustave Roussy - Cancer Campus, Villejuif, FR

08:50 - 08:50 **Session DOI**

08:50 - 09:10 **Pancreatic cancer**

A. Biankin, University of Glasgow - Wolfson Wohl Cancer Research Centre - Institute of Cancer Sciences, Bearsden, GB

09:10 - 09:30 **Glioblastomas**

R. Verhaak, Jackson Laboratory for Genomic Medicine, Farmington, US

09:30 - 09:50 **Biliary tract cancer**

L. Goyal, Massachusetts General Hospital, Harvard Medical School, Boston, US

09:50 - 10:10 **Sarcoma**

J.-Y. Blay, Centre Léon Bérard, Lyon, FR

10:10 - 10:20 **10 - 100,000 genomes project: Integrating whole genome sequencing (WGS) data into clinical practice**

A. Sosinsky¹, J. Ambrose², M. Zarowiecki², J. Mitchell², S. Henderson², N. Murugaesu², A. Hamblin², C. Turnbull³, S. Walker², D. Perez-Gil², A. Rueda-Martin², T. Fowler², M. Caulfield², A. Rendon², ¹QMUL, London, GB, ²Genomics England, London, GB, ³The Institute of Cancer Research (ICR), London, GB

10:20 - 10:30 **20 - Pan-genome cfDNA methylation analysis of metastatic prostate cancer**

A. Wu¹, P. Cremaschi², D. Wetterskog², V. Conteduca³, G.M. Franceschini⁴, E. Gonzalez-Billalebeita⁵, U.D. Giorgi³, F. Demichelis⁴, S. Lise⁶, G. Attard², ¹National Taiwan University College of Medicine, Taipei City, TW, ²University College London Cancer Institute, London, GB, ³Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), meldola, IT, ⁴Centre for Integrative Biology, University of Trento, Povo TN, IT, ⁵Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Murcia,, ES, ⁶Centre for Evolution and Cancer, The Institute of Cancer Research, Surrey, GB

10:30 - 11:00 Coffee break

Britten room

11:00 - 12:20 Clonal evolution

Fleming room

Moderation: S. Turajlic, Royal Marsden Hospital NHS Foundation Trust, London, GB

11:00 - 11:00 Session DOI

11:00 - 11:20 Tracking evolution in prostate cancer with cfDNA profiling

G. Attard, University College London Cancer Institute, London, GB

11:20 - 11:40 Tweaking DNA repair pathways to improve cancer immune surveillance

A. Bardelli, Istituto di Candiolo - FPO - IRCCS, Candiolo, IT

11:40 - 12:00 Clonal evolution of metastatic disease

S. Turajlic, Royal Marsden Hospital NHS Foundation Trust, London, GB

12:00 - 12:10 3O - Temporal dissection of altered pathways during the evolution of cancer

J. Ahrenfeldt¹, M. Sokac², N. Birkbak³, ¹Institute of Clinical Medicine, Aarhus University Hospital Skejby, Aarhus, DK, ²Institute of Clinical Medicine, Aarhus University Hospital Skejby, Aarhus N, DK, ³Institute for Clinical Medicine, Aarhus N, DK

12:10 - 12:20 4O - Tumour cells mirror embryonic developmental programs to acquire invasive and metastatic capabilities

S. Saghafinia, I. Michael, K. Homicsko, D. Hanahan, EPFL - Swiss Institute for Experimental Cancer Research (ISREC), Lausanne, CH

| | | |
|----------------------|---|---------------------|
| 12:20 - 13:05 | Industry satellite - Bayer: Precision oncology: Focus on TRK fusion cancer | Fleming room |
|----------------------|---|---------------------|

12:20 - 12:25 **Welcome and Introduction**

12:25 - 12:35 **Taking action: Using TRK inhibitors to treat TRK fusion cancer**

P. Quirke, Leeds University, Leeds, GB

12:35 - 12:45 **Maximising therapeutic impact: Detection algorithms for NTRK gene fusions**

F. Lopez-Rios Moreno, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES

12:45 - 12:55 **Interactive case session**

12:55 - 13:05 **Q&A and Meeting Close**

P. Quirke, Leeds University, Leeds, GB

13:15 - 14:00 Lunch and poster viewing

Britten room

13:15 - 13:15 **9P - Plasma gene conversions after one cycle (C) abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC): A biomarker analysis of a multi-centre, international trial**

A. Jayaram¹, D. Shen², A. Wingate³, D. Wetterskog⁴, C. Sternberg⁵, R. Jones⁶, A. Berruti⁷, F. Lefresne⁸, M. Lahaye⁹, S. Thomas¹⁰, S. Joshi¹¹, M. Gormley¹⁰, B. Tombal¹², A. Merseburger¹³, D. Ricci¹⁰, G. Attard⁴, ¹The Institute of Cancer Research (ICR), London, GB, ²14. Janssen Research and Development, Spring House PA, US, ³UCL Cancer Institute, London, GB, ⁴University College London Cancer Institute, London, GB, ⁵Weill Cornell Medicine, New York, New York, US, ⁶The Beatson West of University of Glasgow Scotland Cancer Centre, Glasgow, GB, ⁷University of Brescia, Spedali Civili Hospital, Brescia, IT, ⁸13. Janssen Research and Development, Beerse, BE, ⁹Janssen Research and Development, Beerse, BE, ¹⁰Janssen Research and Development, Spring House PA, US, ¹¹HireGenics, Duluth, GA, US, ¹²Université Catholique de Louvain, Brussels, BE, ¹³University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, DE

13:15 - 13:15 **10P - Circulating miR-652-3p as a biomarker of drug resistance in metastatic colorectal cancer patients**

S. Hedayat¹, A. Lampis², G. Vlachogiannis³, K. Khan², D. Cunningham⁴, S. Marchetti², M. Fassan⁵, R. Begum⁶, M. Schirripa⁷, F. Loupakis⁷, N. Valeri⁸, ¹Institute of Cancer Research, London, GB, ²The Institute of Cancer Research (ICR), London, GB, ³Institute of Cancer Research, NG, GB, ⁴The Royal Marsden NHS Trust, PT, GB, ⁵University of Padua, Padoa, IT, ⁶The Royal Marsden NHS Trust, Sutton, LONDON, GB, ⁷Istituto Oncologico Veneto - IRCCS, Padua, IT, ⁸The Institute of Cancer Research (ICR), Sutton, LONDON, GB

13:15 - 13:15

Last update: 08-11-2019 11:51:30am

Programme

11P - Molecular determinants of interaction between glioblastoma CD133+ cancer stem cells and extracellular matrix

I. Bryukhovetskiy¹, Y. Khotimchenko¹, V. Shevchenko², ¹Far Eastern Federal University, Vladivostok, RU, ²N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia, Moscow, RU

13:15 - 13:15

12P - Impact of β-catenin phosphorylation patterns on tumour control/progression in a prospective cervical cancer study (RAIDs)

S. Scholl¹, A. Latouche¹, L. De Koning¹, M. Popovic², A. De La Rochefordière¹, E. Berns³, P. Gestraud¹, E. Girard¹, C. Lecerf¹, H. Von Der Leyen⁴, S. Roman Roman¹, R. Rouzier¹, M. Kamal¹, R. Consortium¹, ¹Institut Curie, Paris, FR, ²Institut of Oncology of Vojvodina, Vojvodina, RS, ³ERASMUS, Rotterdam, NL, ⁴HCTC, hannover, DE

13:15 - 13:15

13P - Using global DNA-methylation and metabolome profiles to classify variants of unknown significance (VUS) in phaeochromocytoma and paraganglioma tumours

S. Williams¹, P. Chatzikyriakou², L. Izatt¹, R. Oakey², ¹Guy's and St. Thomas' Hospital NHS Trust, London, GB, ²King's College London, London, GB

13:15 - 13:15

14P - Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of response to DNA damage

A. Lampis¹, P. Carotenuto², S. Hedayat¹, M. Previdi¹, D. Zito¹, F. Sclafani³, C. Parisi³, J. Hahne¹, A. Hallsworth¹, V. Kirkin¹, K. Young³, K. Kouvelakis³, S. Azevedo³, M. Vasiliki³, A. Scarpa⁴, D. Cunningham³, I. Chau³, N. Valeri¹, M. Fassan⁴, C. Braconi⁵, ¹The Institute of Cancer Research (ICR), Sutton, LONDON, GB, ²The Institute of Cancer Research, Sutton, LONDON, GB, ³The Royal Marsden NHS Trust, Sutton, LONDON, GB, ⁴University of Padua, Padua, IT, ⁵The Institute of Cancer Sciences, University of Glasgow, Glasgow, GB

13:15 - 13:15

15P - Mechanistic insight into anti-cancer activity of plumbagin in endocrine resistant and HER2-overexpressed breast cancer cells

N. Sakunrangsit¹, W. Ketchart², ¹King Chulalongkorn Memorial Hospital, Bangkok, TH, ²Faculty of Medicine, Chulalongkorn University, Bangkok, TH

13:15 - 13:15

16P - Dual MGMT inactivation by promoter hypermethylation and loss of chromosome 10q as relevant prognostic marker in glioblastoma

G. Tachon¹, S. Richard², S. Milin¹, M. Wager¹, L. Karayan-Tapon³, ¹CHU Poitiers - Jean Bernard Hôpital, Poitiers, FR, ²University of Poitiers, Poitiers, FR, ³INSERM 1084, Poitiers, FR

13:15 - 13:15

17P - Genomic profiling of non-oncogene-addicted aNSCLC using liquid biopsy. A single institution Italian experience

R. Di Liello¹, G. Viscardi¹, F. Sparano¹, C.M. Della Corte¹, M.L. Iacovino¹, F. Paragliola¹, V. Famiglietti², A. Di Liello², F. Ciardiello¹, F. Morgillo¹, ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²Università degli Studi della Campania Luigi Vanvitelli, Naples, IT

- 13:15 - 13:15 **18P - Clinical outcome of personalised treatment guided by genome and transcriptome sequencing in patients with neuroendocrine neoplasms: Updated results from the German NCT/DKTK MASTER trial**
S. Kreutzfeldt¹, L. Apostolidis², M. Oles³, P. Horak⁴, C. Heilig⁵, C. Heinig⁶, B. Hutter¹, B. Klink⁷, M. Lamping⁸, S. Uhrig¹, A. Stenzinger⁹, E. Winkler³, B. Wiedenmann¹⁰, D. Jäger³, B. Brors¹, E. Schröck¹¹, U. Keilholz⁸, M. Pavel¹², H. Glimm⁶, S. Fröhling¹³,
¹German Cancer Research Center, Heidelberg, DE, ²University Hospital Heidelberg, Heidelberg, DE, ³NCT Heidelberg, Heidelberg, DE, ⁴Donauspital im SMZ-Ost, Vienna, AT, ⁵University of Heidelberg, Heidelberg, DE, ⁶NCT Dresden, Dresden, DE, ⁷Université du Luxembourg, Dudelange, LU, ⁸Charité - Universitätsmedizin Berlin, Berlin, DE, ⁹University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE, ¹⁰Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ¹¹Faculty of Medicine Carl Gustav Carus, Dresden, DE, ¹²Universitätsklinik Erlangen, Erlangen, DE, ¹³German Cancer Research Center (DKFZ), Heidelberg, DE
- 13:15 - 13:15 **19P - JAK3 defines a unique molecular subtypes of East Asian non-small cell lung cancer patients**
C. Xu¹, W. Wang², Q. Zhang¹, W. Zhuang¹, Y. Zhu³, Z. Huang¹, G. Chen¹, M. Fang², T. Lv⁴, Y. Song⁴, ¹Fujian Cancer Hospital, Fuzhou, CN, ²Zhejiang Cancer Hospital, Hangzhou, CN, ³Zhejiang Rongjun Hospital, Jiaxing, CN, ⁴Jinling Hospital, Nanjing, CN
- 13:15 - 13:15 **20P - Detecting therapy-guiding aberrations in platelets and plasma at the transcriptome level in non-small-cell lung cancer**
P. Meng¹, A. Rybczynska¹, J. Wei¹, M. Terpstra², W. Timens¹, E. Schuuring¹, T. Hiltermann³, H. Groen¹, K. Kok¹, A. Van Der Wekken¹, A. Van Den Berg¹, ¹University Hospital Groningen (UMCG), Groningen, NL, ²University of Groningen, University Medical Center Groningen (UMCG), Groningen, NL, ³University Medical Center Groningen (UMCG), Groningen, NL
- 13:15 - 13:15 **21P - The different prognostic impact of age according to individual molecular subtypes in breast cancer**
Y.H. Eom, Seoul St. Mary's Hospital, of the Catholic University, Seoul, KR
- 13:15 - 13:15 **22P - Feasibility of precision cancer medicine in advanced gynaecologic cancers**
H. Taghizadeh¹, R. Mader², L. Müllauer³, S. Aust⁴, S. Polterauer³, A. Reinthaller³, H. Kölbl³, V. Seebacher⁵, C. Grimm⁶, G. Prager⁵, ¹Medical University of Vienna, Wien, AT, ²Medical University of Vienna, Viennna, AT, ³Medical University of Vienna, Vienna, AT, ⁴Medizinische Universitaet Wien, Vienna, AT, ⁵Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, ⁶Medizinische Universitaet Wien (Medical University of Vienna), Vienna, AT
- 13:15 - 13:15 **23P - A new quercetin glycoside enhances TNBC immunological profile through TP53/miR-155/MICA/ULBP2**
M. Abdel-Latif¹, A. Afifi¹, R. Soliman¹, A. Elkhouly¹, A. Abdelmotaal², R. Youness¹, ¹German University in Cairo, Cairo, EG, ²Faculty of Pharmacy, King Khalid University, Cairo, EG

13:15 - 13:15 **24P - Therapeutic implications of MTH1 inhibitor TH1579 in cutaneous malignant melanoma**

I. Das, H. Gad, L. Bräutigam, L. Pudelko, R. Tuominen, V. Höiom, I. Almlöf, J. Hansson, T. Helleday, S.E. Brage, U.W. Berglund, Karolinska Institute, Stockholm, SE

13:15 - 13:15 **25P - Low pass whole genome sequencing can be used to calculate the relative proportion of chemotherapy resistant disease in high grade serous ovarian cancer**

H. Hockings¹, M. Mossner², E. Lakatos², T. Graham¹, M. Lockley¹, ¹Barts Cancer Institute-Queen Mary University of London, London, GB, ²Barts Cancer Institute, London, GB

13:15 - 13:15 **26P - A combination of resistance mechanisms is frequent in non-small cell lung cancer (NSCLC) that progressed to EGFR tyrosine kinase inhibitors (TKIs)**

D. Enrico¹, L. Lacroix¹, E. Rouleau¹, J.-Y. Scoazec¹, Y. Loriot¹, L. Tselikas¹, C. Jovelet¹, D. Planchard¹, A. Gazzah¹, L. Mezquita¹, M. Ngo¹, S. Michiels¹, A. Maillard¹, C. Massard¹, F. Facchinetto¹, J.-C. Soria¹, F. André², G. Vassal¹, L. Friboulet¹, B. Besse¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Gustave Roussy - Cancer Campus, Villejuif, FR

13:15 - 13:15 **27P - Artemisia absinthium nanoparticles induce apoptosis in breast cancer cells via inhibiting vesicular trafficking related proteins**

M. Mughees¹, S. Wajid², ¹Jamia Hamdard University, New Delhi, IN, ²Jamia Hamdard, New Delhi, IN

13:15 - 13:15 **28P - CNAs concordance between CRC-PDOs and the original tissue reveals relevant oncogenic pathways alterations**

F. Papaccio¹, F. Valiente², M.F. Gutierrez-Bravo³, M. Cabeza-Segura², V. Gambardella², M.D.S. Huerta³, C. Martinez-Ciarpaglini³, C. Alfaro-Cervello³, P. Rentero-Garrido³, S. Zúñiga-Trejos³, S. Rosello Keranen⁴, T. Fleitas⁴, N. Tarazona², D. Roda Perez⁴, A. Cervantes⁴, J. Castillo⁵, ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²INCLIVA Instituto de investigación sanitaria, Valencia, ES, ³INCLIVA Biomedical Research Institute, Valencia, ES, ⁴Hospital Clínico Universitario de Valencia, Valencia, ES, ⁵Universidad de Valencia, Valencia, ES

13:15 - 13:15 **29P - A retrospective analysis of 66 colorectal cancer cases from Guy&&**

M. Kapiris¹, D. Josephs¹, A. Kulkarni¹, M. Valganon², B. De Souza¹, J. Campbell¹, F. Churm¹, G. Nickless¹, P. Ross¹, J. De Naurois¹, N. Maisey¹, K. Thillai¹, J. Roca¹, M. George¹, A. Schizas¹, V. Datta¹, E. Westcott¹, D. Sarker¹, ¹Guy's and St. Thomas' Hospital NHS Trust, London, GB, ²Imperial College London - Hammersmith Hospital, London, GB

13:15 - 13:15 **30P - Protein interactome network analysis predicts novel breast cancer candidate genes with molecular signatures**

M. Peer Mohammed, Bioinformatics Infrastructure Facility, Tamilnadu, IN

13:15 - 13:15 **31P - Tepotinib inhibits the epithelial-mesenchymal transition and tumour growth of gastric cancers via decreasing MUC5B, MMP7, and COX2**

D.Y. Zang¹, S.-H. Sohn², H.J. Sul², B. Kim², B.Y. Choi², H.S. Kim¹, ¹Hallym University Medical Center-Hallym University College of Medicine, Anyang, KR, ²Hallym University Sacred Heart Hospital, Anyang, KR

13:15 - 13:15 **32P - Application of variant interpretation software to decipher pathogenicity of mutations for a molecular tumour board (MTB)**

S. Southam¹, M. Ayub¹, M. Krebs², D. Rothwell¹, D. Graham², J. Stevenson¹, ¹Cancer Research UK Manchester Institute, Manchester, GB, ²The Christie NHS Foundation Trust, Manchester, GB

13:15 - 13:15 **33P - Combination of mTOR inhibition and paclitaxel as a personalised strategy in the context of MYC-amplified high-grade serous ovarian cancer**

F. Martins¹, D.-L. Couturier², I. De Santiago², M. Vias², D. Sanders², A. Piskorz², J. Hall², M. Jimenez-Linan³, K. Hosking³, R. Crawford³, J. Brenton², ¹Cancer Research UK & University of Cambridge UK, Cambridge, GB, ²Cancer Research UK Cambridge Institute, Cambridge, GB, ³Cambridge University Hospitals, Cambridge, GB

13:15 - 13:15 **34P - The importance of p53 signaling pathway in the evolution of gastric cancer**

S. Gurzu¹, H. Sugimura², R. Van Staden³, H. Yamada², I. Jung¹, ¹University of Medicine and Pharmacy Targu-Mures, Targu Mures, RO, ²Hamamatsu University School of Medicine, Hamamatsu, JP, ³National Institute of Research for Electrochemistry and Condensed Matter, Bucharest, Romania, Bucharest, RO

13:15 - 13:15 **35P - Patterns of N-cadherin (N-cad) and vimentin (Vim) expression as a sign of epithelial-mesenchymal transition (EMT) in prostate cancer (PCa)**

M. Puchinskaya, Minsk City Clinical Oncologic Dispensary, Minsk, BY

13:15 - 13:15 **36P - Results of a first panTRK IHC ringtrial**

K. De Winne¹, L. Sorber², S. Lambin¹, L. Keulen¹, G. Broeckx¹, P. Pauwels¹, K. Zwaenepoel³, ¹Antwerp University Hospital, Edegem, BE, ²University of Antwerp, Wilrijk, BE, ³University Hospital Antwerp (UZA), Edegem, BE

13:15 - 13:15 **37P - Plasma ctDNA RAS mutation analysis by digital polymerase chain reaction in patients with inoperable pancreatic cancer**

S. Gkoura¹, M. Kastrisiou², A. Kougioumtzi³, C. Tzallas¹, K. Gkrepi¹, A. Goussia⁴, A. Magklara³, G. Pentheroudakis¹, ¹University Hospital of Ioannina, Ioannina, GR, ²University of Ioannina Medical Faculty, Ioannina, GR, ³University of Ioannina Medical School, Ioannina, GR, ⁴University of Ioannina Faculty of Medicine, Ioannina, GR

13:15 - 13:15 **38P - Anti-breast cancer activity of 7-α-hydroxyfrullanolide triggered G2/M arrest and apoptotic induction of triple negative breast cancer cell line, revealed by proteomics**

S. Chimplee¹, S. Roytrakul², P. Grajdist³, S. Sukrong⁴, T. Srisawat⁵, K. Kanokwiroom³, ¹Prince of Songkla University - Faculty of Medicine - Songkhlanagarind Hospital, Hat Yai, TH, ²Genome Institute National Center for Genetic Engineering and Biotechnology (BIOTEC), Pathum Thani, TH, ³Prince of Songkla University, Faculty of Medicine, Hat Yai,

Songkhla, TH, ⁴Research Unit of DNA Barcoding of Thai Medicinal Plants, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, TH, ⁵Faculty of Science and Industrial Technology, Prince of Songkla University, Surat Thani Campus, Surat Thani, TH

13:15 - 13:15 **39P - Exploring the role of the DDB2 protein as a potent molecular target in pancreatic ductal adenocarcinoma**

P. Gilson¹, M. Meras¹, M. Ariztegui¹, P. Becuwe², J.-L. Merlin¹, A. Harlé¹, ¹Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, ²Université de Lorraine, CNRS UMR 7039 CRAN, Faculté des Sciences et Technologies,, Vandoeuvre les Nancy, FR

13:15 - 13:15 **40P - Prognostic role of APOBEC3 genes mRNA expression in lower grade glioma**

K. Ismaeil, Ain Shams University Faculty of Medicine, Cairo, EG

13:15 - 13:15 **41P - Customisation of therapeutic strategy in metastatic colorectal cancer by use of liquid biopsies: Updated results of an observational study**

M. Kastrisou¹, G. Zarkavelis², A. Kougioumtzi³, C. Tzallas², E. Saloustros⁴, A. Kotsakis⁵, E. Papadopoulou⁶, G. Nasioulas⁷, A. Batistatou³, A. Magklara⁸, G. Pentheroudakis², ¹University of Ioannina Faculty of Medicine, Ioannina, GR, ²University Hospital of Ioannina, Ioannina, GR, ³University of Ioannina Medical Faculty, Ioannina, GR, ⁴University General Hospital of Larissa, Larissa, GR, ⁵University Hospital of Heraklion, Heraklion, GR, ⁶Genekor s.a, Pallini, GR, ⁷Genekor Medical S.A., Gerakas, GR, ⁸University of Ioannina Medical School, Ioannina, GR

13:15 - 13:15 **42P - Prediction of PFS using a dynamic assessment of ctDNA in patients with EGFR mutated NSCLC with osimertinib therapy**

F. Moiseenko¹, M. Stepanova², A. Zhabina¹, A. Myslik¹, V. Klimenko¹, N. Rysev¹, E. Artemieva¹, K. Shelekhova¹, A. Bogdanov¹, N. Volkov¹, V. Moiseenko¹, ¹St. Petersburg Clinical Research Center of specialized types of care (Oncology), St. Petersburg, RU, ²N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, RU

13:15 - 13:15 **43P - Targeted high-throughput sequencing for somatic mutations identification in thyroid cancer management**

V. Yakushina¹, L. Lerner², T. Avdeeva³, T. Kazubskaya⁴, T. Kondrat'ieva⁴, A. Lavrov¹, ¹Research Centre for Medical Genetics, Moscow, RU, ²PreMed-European Technologies, Moscow, RU, ³Moscow City Clinical Hospital after V.M. Buyanov, Moscow, RU, ⁴N.N. Blokhin Russian Cancer Research Center, Moscow, RU

13:15 - 13:15 **44P - Association of metastatic pattern and molecular status in metastatic lung non-small cell lung cancer adenocarcinomas**

A. Dormieux¹, L. Mezquita², P.-H. Courneuve³, L. Lacroix², E. Rouleau², J. Adam², F. Facchinetti², F. Aboubakar², M.-V. Bluthgen², C. Naltet², P. Lavaud², A. Gazzah², C. Le Pechoux², C. Balleyguier², D. Planchard², B. Besse², C. Caramella², ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Institut Gustave Roussy, Villejuif, FR, ³centraleSupélec, Gif-sur-yvette, FR

13:15 - 13:15 **45P - Circulating tumour associated cells in esophageal cancers are resistance**

educated per previous chemo treatments

S. Limaye¹, T. Crook², A. Ranade³, D. Patil⁴, D. Akolkar⁴, V. Datta⁴, S. Schuster⁵, R. Page⁶, C. Sims⁴, R. Patil⁴, A. Srinivasan⁴, S. Khan⁴, S. Patil⁴, V. Mhase⁴, S. Apurwa⁴, R. Datar⁴, ¹Kokilaben Dhirubhai Ambani Hospital, Mumbai, IN, ²Royal Surrey County Hospital, Guildford, GB, ³Avinash Cancer Clinic, Pune, IN, ⁴Datar Cancer Genetics, Nashik, IN, ⁵Datar Cancer Genetics Europe GmbH, Bayreuth, DE, ⁶Worcester Polytechnic Institute, Worcester, US

13:15 - 13:15

46P - Prevalence of homologous recombination deficiency (HRD)-related signatures indicates that a wider range of prostate cancer patients may benefit from PARP-inhibitor therapy

Z. Sztupinszki¹, M. Dioissy¹, M. Krzystanek², J. Borcsok¹, M. Pomerantz³, V. Tisza⁴, S. Spisak³, O. Rusz⁵, I. Csabai⁶, M. Freedman³, Z. Szallasi⁴, ¹The Danish Cancer Society, Copenhagen, DK, ²Technical University of Denmark, Lyngby, DK, ³Dana-Farber Cancer Institute, Boston, US, ⁴Boston Children's Hospital, Boston, US, ⁵Semmelweis University, Budapest, HU, ⁶Department of Physics of Complex Systems, Budapest, HU

13:15 - 13:15

47P - The properties of mitochondria in glioma stem cells

N. Hong, E.-J. Kim, H. Kim, Korea University, Seoul, KR

13:15 - 13:15

48P - PLSCR1 and XKR8: New markers for low-grade glioma progression and outcome

K. Havrysh¹, M. Bogdanov², R. Kiyamova³, ¹Taras Shevchenko National University of Kyiv, Educational and scientific centre "Institute of biology", Kiev, UA, ²Center for Membrane Biology, University of Texas McGovern Medical School at Houston, Texas, US, ³Kazan Federal University, Kazan, RU

13:15 - 13:15

49P - An exceptional response to immunotherapy doublet in combined hepatocellular carcinoma-cholangiocarcinoma

E. Tahover, Shaare Zedek Medical Center, Jerusalem, IL

13:15 - 13:15

50P - Assessing melanoma BRAF status through ddPCR of cfDNA

L. Passby, S. Silva, I. Brock, G. Wells, A. Cox, S. Danson, University of Sheffield Medical School, Sheffield, GB

13:15 - 13:15

51P - LIMCH1-related genes demonstrate different invasive potential of morphological structures of breast cancer

L. Tashireva, T. Gerashchenko, V. Alifanov, V. Perelmuter, N. Cherdynseva, Cancer Research Institute - Tomsk National Research Medical Center, Tomsk, RU

13:15 - 13:15

53P - ZNF518B as a transcriptional factor involved in colorectal cancer progression through the epithelial to mesenchymal transition

F. Valiente¹, N. Tarazona¹, V. Gambardella¹, Á. Riffó-Campos², F. Papaccio³, M. Cabeza-Segura¹, G. López-Rodas⁴, A. Cervantes⁵, L. Franco⁴, J. Castillo⁴, ¹INCLIVA Instituto de investigación sanitaria, Valencia, ES, ²University of La Frontera, Temuco, CL, ³Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ⁴Universidad de Valencia, Valencia, ES, ⁵Hospital Clínico Universitario de Valencia, Valencia, ES

13:15 - 13:15 **54P - Investigation of the mechanisms of resistance to osimertinib in patients with T790M-associated NSCLC**

M. Stepanova¹, F. Moiseenko², A. Zhabina², V. Klimenko², N. Rysev², A. Myslik², E. Artemieva², K. Shelekhova², A. Bogdanov², N. Volkov², V. Moiseenko², ¹N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, RU, ²St. Petersburg Clinical Research Center of specialized types of care (Oncology), St. Petersburg, RU

13:15 - 13:15 **55P - NGS-based multi-gene panel analysis in early-onset colorectal cancer patients**

G. Zhunussova¹, G. Afonin², S. Abdikerim³, A. Jumanov⁴, A. Perfilyeva³, D. Kaidarova⁴, L. Djansugurova³, ¹Institute of general genetics and cytology, Almaty, KZ, ²1) Kazakh Institute of Oncology and Radiology, Almaty, KZ, ³Institute of General Genetics and Cytology, Almaty, KZ, ⁴1) Kazakh Institute of Oncology and Radiology. 2)Asfendiyarov Kazakh National Medical University, Almaty, KZ

13:15 - 13:15 **56P - Ibrutinib for relapsed/refractory mantle cell lymphoma: 7-year experience**

I. Grilo¹, M.E. Couto², J.F. Freitas², D.P. Pereira², C. Moreira², S. Chacim², N. Domingues², A. Santo², Â. Martins², L. Viterbo², I. Oliveira², I. Moreira², J. Mariz², ¹Centro Hospitalar Tras-os-Montes e Alto Douro, E.P.E., Vila Real, PT, ²IPO-Porto, Porto, PT

13:15 - 13:15 **57P - Leukotriene B4 receptors abnormal gene expression is associated with either shorter or longer survival in breast cancer patients depending on the intrinsic tumour molecular subtype**

A. Kalinkin¹, M. Nemtsova², D. Zaletaev², V. Sigin³, E. Ignatova⁴, E. Kuznetsova³, V. Strelnikov³, A. Tanas³, ¹Federal State Budgetary Institution Research Centre for Medical Genetics, Moscow, RU, ²Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, RU, ³Research Centre for Medical Genetics, Moscow, RU, ⁴FSBI-N. N. Blokhin Russian Cancer Research Center, Moscow, RU

13:15 - 13:15 **58P - A seven-gene methylation markers panel: An epigenetic predictor of neoadjuvant chemotherapy sensitivity in triple-negative breast cancer**

V. Sigin¹, A. Kalinkin¹, E. Ignatova², A. Sycheva¹, I. Vinogradov³, M. Vinogradov⁴, I. Vinogradov³, D. Zaletaev⁵, V. Strelnikov⁶, A. Tanas⁶, ¹Federal State Budgetary Institution "Research Centre for Medical Genetics", Moscow, RU, ²FSBI-N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ³Ryazan Regional Clinical Oncology Dispensary, Ryazan, RU, ⁴Ryazan State Medical University, Ryazan, RU, ⁵Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, RU, ⁶Research Centre for Medical Genetics, Moscow, RU

13:15 - 13:15 **59P - Not only gene mutation matters: Development of flow cytometry panel to determine BRCA2 deficiency for personalised therapy by PARP inhibitors in pancreatic cancers**

P. Chroscicki¹, A. Tybuchowska¹, J. Swatler¹, R. Samsel², A. Cichocki², P. Podszyalow-

Bartnicka¹, K. Roszkowska-Purska², M. Tenderenda², W. Smiertka², M. Nieborowska-Skorska³, T. Skorski³, K. Piwocka¹, ¹Nencki Institute of Experimental Biology, Warsaw, PL, ²Maria Skłodowska-Curie Institute - Oncology Center, Warszawa, PL, ³Temple University Lewis Katz School of Medicine, Philadelphia, US

13:15 - 13:15 **60P - Evaluation of mouse polyclonal antibody against nNav1.5 to recognize nNav1.5 protein in human breast cancer cells using fluorescence immunostaining**

N.F. Mokhtar, N.A. Sharuddin, N.F.A. Che Wahab, A.A. Dominguez, M.E. Sarmiento, N. Mohd Nor, N.S. Yacob, Universiti Sains Malaysia (USM) Health Campus, Kota Bharu, MY

13:15 - 13:15 **61P - Role of molecular markers in glioblastoma patients of Pakistan**

Y. Mirza, S.M.A. Ali, S.A. Enam, The Aga Khan University, Karachi, PK

13:15 - 13:15 **62P - Identification of tamoxifen-resistant microRNA expression profiles in breast cancer: En route to precision medicine through establishing new biomarkers**

O. Andreeva, S. Semina, A. Scherbakov, M. Krasil`Nikov, N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU

13:15 - 13:15 **63P - Nrf2 expression in surgically resected lung adenocarcinomas: Its association with clinicopathologic features and driver oncogene alterations**

K. Takamochi¹, T. Hayashi², K. Hara², Y. Mitsuishi², F. Takahashi², Y. Suehara², K. Suzuki², ¹Juntendo University International Center (JUIC), Tokyo, JP, ²Juntendo University School of Medicine, Tokyo, JP

13:15 - 13:15 **64P - Role of RNF144B in triple negative breast cancer proliferation**

L. Altarjami, Manchester University, Manchester, GB

13:15 - 13:15 **65P - Potentially actionable mutations in intrahepatic cholangiocarcinoma**

G. Frega¹, S. Tavolari², V. Indio³, M. Deserti², G. Tarantino³, A. Palloni⁴, S. De Lorenzo⁴, A. Rizzo⁴, A. Astolfi³, G. Brandi⁴, ¹AOU Policlinico S. Orsola-Malpighi, F.Addarii, Bologna, IT, ²Center for Applied Biomedical Research, Bologna, IT, ³"Giorgio Prodi" Cancer Research Center, University of Bologna, Bologna, IT, ⁴Department of Experimental, Diagnostic and Specialty Medicine, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, IT

13:15 - 13:15 **66P - Customized hepatocellular carcinoma prediction panel**

A. Abramov, A. Petkevich, P. Ogurtsov, M. Hassan-Kadle, Peoples' Friendship University of Russia (RUDN University), Moscow, RU

13:15 - 13:15 **67P - Circulating tumour cells mRNA in treatment strategy for melanoma**

A. Abramov, A. Petkevich, P. Ogurtsov, Peoples' Friendship University of Russia (RUDN University), Moscow, RU

13:15 - 13:15 **68P - C-met mediates invasion and chemotherapy resistance in high grade serous ovarian cancer**

G. Wood¹, M. Lockley², S. Kermorgant², ¹Poole hospital NHS Foundation Trust, Poole, GB, ²Barts Cancer Institute-Queen Mary University of London, London, GB

13:15 - 13:15 **69P - A laboratory assay for improved prediction of drug responses in acute myeloid leukaemia cells**

E. Aleem¹, J. Montoya², D. Lee³, K. Finch⁴, D. Wai³, C. Dubois⁵, ¹London South Bank University, London, GB, ²Phoenix Children's Hospital, Phoenix, US, ³Phoenix Children Hospital, Phoenix, US, ⁴University of Arizona College of Medicine phoenix, Phoenix, US, ⁵University of Arizona College of medicine phoenix, Phoenix, US

13:15 - 13:15 **70P - Improving personalised therapy in metastatic breast cancer by implementing RNA sequencing based gene expression signatures**

M. Schulze¹, M. Hlevnjak², V. Thewes³, S. Elgaafary⁴, A. Mavratzas⁴, S. Fröhling⁵, J. Seitz⁴, M. Zapatka², P. Lichter⁶, A. Schneeweiss⁴, ¹German Cancer Research Center, Heidelberg, DE, ²German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, DE, ³German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) and National Center for Tumor Diseases, University of Heidelberg, Heidelberg, DE, ⁴National Center for Tumor Diseases, University of Heidelberg and German Cancer Research Center (DKFZ), Heidelberg, DE, ⁵German Cancer Research Center (DKFZ), Heidelberg, DE, ⁶German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ) and DKFZ-Heidelberg Center for Personalized Oncology (DKFZ-HIPO), German Cancer Research Center (DKFZ), Heidelberg, DE

13:15 - 13:15 **71P - Evaluation of miRNA-135a and miRNA-9 as prognostic markers in breast cancer patients**

M. Gamea, Aswan University, Aswan, EG

13:15 - 13:15 **72P - Retrospective study evaluating the impact of genomic profiling on management of patients with metastatic breast cancer**

A. Amin, Alexandria clinical oncology department, Alexandria, EG

13:15 - 13:15 **73P - Overexpression of EGFR, COX2 and p53 in oral squamous cell carcinoma patients of Pakistan and correlation with prognosis**

S.M.A. Ali, Y. Mirza, The Aga Khan University, Karachi, PK

13:15 - 13:15 **74P - HER2 Ile655Val polymorphism, EGFR expression and cellular proliferation in urinary bladder carcinomas**

M. Dumitru¹, M. Gruia¹, A. Botezatu², M. Mihaila², C. Hotnog², M. Hortopan³, M. Panait¹, G. Anton², L. Brasoveanu², ¹Institutul Oncologic Profesor Doctor Alexandru Trestioreanu, Bucharest, RO, ²S. Nicolau Institute of Virology, Bucharest, RO, ³Clinical Institute Fundeni, Bucharest, RO

13:15 - 13:15 **75P - Dynamics of ctDNA in patients with NSCLC**

A. Zhabina¹, A. Mjslik², F. Moiseenko³, V. Moiseenko³, M. Stepanova¹, ¹N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, RU, ²Clinical Scientific and Practical Oncology Center, Spb, RU, ³St. Petersburg Clinical Research Center of specialized types of care (Oncology), St. Petersburg, RU

13:15 - 13:15 **77P - Molecular: Genetic analysis of uterine carcinosarcomas**

N. Levitskaya¹, O. Vostryukhina², I. Poddubnaya³, ¹Ministry of Healthcare of Moscow, Moscow, RU, ²Petersburg Nuclear Physics Institute named by B.P.Konstantinov of NRC «Kurchatov Institute», Saint Petersburg, RU, ³Russian Medical Academy for Continuous Professional Education, Moscow, RU

13:15 - 13:15 **78P - Ly6G+ cells in irradiated tumour tissue promote glioblastoma cell dedifferentiation and tumour recurrence**

S. Seo, H.-Y. Jeon, H. Kim, Korea University, Seoul, KR

13:15 - 13:15 **79P - Cell lineage context and type of genomic alteration predict for the therapeutic relevance of tyrosine kinase inhibitors in human cancers**

H. Vanacker¹, P. Cassier¹, M. Pérol¹, P. Saintigny¹, L. Eberst¹, M. Carbonnaux¹, M. Brahmi¹, L. Verlingue², I. Ray-Coquard¹, D. Pérol¹, J.-Y. Blay¹, ¹Centre Léon Bérard, Lyon, FR, ²Institut Gustave Roussy, Villejuif, FR

13:15 - 13:15 **80P - Magnetic nanovector for the down regulating CD44 and imaging of microRNA34a**

H. Lee, Yonsei University College of Medicine, Seoul, KR

13:15 - 13:15 **81P - Comprehensive genomic and transcriptomic profiling in advanced-stage cancers and rare malignancies: Clinical results from the MASTER trial of the German Cancer Consortium**

P. Horak¹, S. Kreutzfeldt², A. Mock³, C. Heining⁴, C. Heilig⁵, L. Möhrmann⁴, S. Uhrig², D. Hübschmann⁵, K. Beck⁵, D. Richter⁴, R. Schlenk⁶, B. Klink⁷, B. Hutter², W. Weichert⁸, A. Stenzinger⁹, E. Schröck¹⁰, B. Brors², H. Glimm¹¹, S. Fröhling⁵, ¹Donauspital im SMZ-Ost, Vienna, AT, ²German Cancer Research Center, Heidelberg, DE, ³NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, ⁴NCT Dresden, Dresden, DE, ⁵NCT Heidelberg, Heidelberg, DE, ⁶Nationales Zentrum für Tumorerkrankungen (NCT), Heidelberg, DE, ⁷Université du Luxembourg, Dudelange, LU, ⁸Technische Universität München-Institute of Pathology, Munich, DE, ⁹University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE, ¹⁰Faculty of Medicine Carl Gustav Carus, Dresden, DE, ¹¹National Center for Tumor Diseases, Partner site Dresden (NCT), Dresden, DE

13:15 - 13:15 **82P - Arcagen: An EORTC-SPECTA project to perform a molecular characterization of rare cancers: Results of the retrospective feasibility cohort**

M. Vinches¹, A. Stevovic², I. Ray-Coquard³, I. Treilleux³, P. Meeus³, S. Aust³, A. Floquet⁴, S. Croce⁴, L. Chalabreysse⁵, N. Girard⁶, J.-Y. Blay³, M. Morfouace², ¹ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ²EORTC - European Organisation for Research and Treatment of Cancer, Bruxelles, BE, ³Centre Léon Bérard, Lyon, FR, ⁴Institute Bergonié, Bordeaux, FR, ⁵Hospices Civils de Lyon, Lyon, FR, ⁶Institut Curie, Paris, FR

13:15 - 13:15 **83P - Radiation-induced change of PD-1/PD-L1 immune checkpoint in mouse colon cancer models**

Y.J. Lim, Kyung Hee University Hospital, Seoul, KR

- 13:15 - 13:15 **84P - Combination treatment of astragalus membranaceus, dose-modified chemotherapy, and anti-PD1 checkpoint inhibitor for patients of advanced malignancy with initial cachexia or poor performance status: A single-institute experience**
H.C. Lai¹, W. Lin¹, T.L. Po², M.J. Yang³, ¹Shin Kong Wu Ho-Su Memorial Hospital, New Taipei city, TW, ²Shin Kong Wu Ho-Su Memorial Hospital, Taipei city, TW, ³3DNArails, Taipei city, TW
- 13:15 - 13:15 **85P - Validation and implementation of a bespoke pan-cancer NGS panel for FFPE solid tumour analysis within an NHS setting**
H. Roberts, S. Wood, E. Mcneil, R. White, S. Morgan, Institute of Medical Genetics - University Hospital of Wales - Cardiff and Vale University Health Board - NHS Wales, Cardiff, GB
- 13:15 - 13:15 **86P - Immune checkpoint molecule V-set Ig domain-containing 4 (VSIG4) expression is associated with poor prognosis in advanced gastric cancer patients**
S.-W. Kim¹, C.-S. Park², J. Roh³, M.-H. Rhu², Y.-S. Park², H.S. Lee², ¹Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ²Asan medical center, Seoul, KR, ³Ajou University School of Medicine, Suwon, KR
- 13:15 - 13:15 **87P - Investigating the role of chromosomal instability in immune cell activation**
M. Sokac¹, L. Dyrskjøt Andersen¹, M. Roelsgaard Jakobsen², N. Birkbak³, ¹Aarhus University Hospital/Skejby Sygehus - Brystklinikken, Aarhus N, DK, ²Aarhus University, Aarhus N, DK, ³Institute for Clinical Medicine, Aarhus N, DK
- 13:15 - 13:15 **88P - Epithelial-mesenchymal transition of tumour buds: A histopathological parameter with potential implication in oncological therapy of colorectal carcinoma**
I. Jung, L. Banias, T. Bara, Z. Kovacs, Z. Fulop, P. Simu, I. Simu, S. Gurzu, University of Medicine, Pharmacy, Sciences and Technology, Targu-Mures, Targu-Mures, RO
- 13:15 - 13:15 **89P - Distribution of somatic mutations in PIK3CA gene in breast colorectal and colorectal Czech cancer patients - selected colorectal cancer patients with angiogenesis inhibitors treatment**
J. Simova¹, I. Urbanovská², R. Měch¹, J. Žmolíková², B. Kubová², K. Vaňáková², L. Trombík², N. Dvořáčková², J. Dvořáčková², J. Drábek³, M. Uvírová², ¹CGB laborator a.s., Ostrava, CZ, ²CGB laboratory Inc., Ostrava, CZ, ³Institute of molecular and translational medicine, Olomouc, CZ
- 13:15 - 13:15 **90P - Patient-derived organoid models of metastatic colorectal cancer to study response to PIK3CA inhibitors**
J.D. Barros Silva, K. Wanigasooriya, H. Bermingham, S. Patel, R. Hoare, A. Stodolna, O. Pickles, C. Bryer, C. Whalley, A. Beggs, Institute of Cancer and Genomic Sciences - University of Birmingham, Birmingham, GB
- 13:15 - 13:15 **91P - Exploration of biologic significances and mechanisms of combined atorvastatin with PI3K/Akt inhibitor in radiotherapy of colorectal cancer**

C.H. Cheng, National Taiwan University Hospital, Taipei City, TW

13:15 - 13:15 **92P - Detection of PIK3CA mutation by circulating DNA during chemotherapy: A tool to identify hard-to-treat metastatic breast cancers**

F. Mosele¹, A. Lusque², A. Tran Dien¹, N. Droin¹, C. Le Tourneau³, M.P. Sablin³, L. Lacroix⁴, I. Miran⁵, C. Jovelet⁴, I. Bieche³, J.-C. Soria⁴, F. Bertucci⁶, H. Bonnefoi⁷, M. Campone⁸, F. Dalenc², T. Bachelot⁹, A. Jacquet¹⁰, M. Jimenez¹⁰, F. André¹, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Institut Claudius Regaud, Toulouse, FR, ³Institut Curie, Paris, FR, ⁴Institut Gustave Roussy, Villejuif, FR, ⁵Gustave Roussy, Villejuif, FR, ⁶Institut Paoli-Calmettes, Marseille, FR, ⁷Institut Bergonie, Bordeaux, FR, ⁸Institut of Cancerology Ouest, Nantes, FR, ⁹Center Leon Berard, Lyon, FR, ¹⁰Unicancer, Paris, FR

13:15 - 13:15 **93P - Preclinical development of a novel, highly selective PI3Kδ inhibitor, IOA-244, for the treatment of solid malignancies**

Z. Johnson¹, E. Papakonstanti², A. Tsapara², A. Macqueen³, P. Shah³, L. Van Der Veen¹, M. Lahn¹, ¹iOnctura SA, Geneva, CH, ²University of Crete, Crete, GR, ³CRUK-TDL, Cambridge, GB

13:15 - 13:15 **94P - Encyclopedic tumour analysis guided treatments with conventional drugs outperform available alternatives in refractory cancers**

T. Crook¹, A. Vaid², S. Limaye³, R. Page⁴, D. Patil⁵, D. Akolkar⁵, V. Datta⁵, A. Ghaisas⁵, R. Patil⁵, H. Singh⁵, A. Srinivasan⁵, S. Apurwa⁵, R. Datar⁵, ¹Royal Surrey County Hospital, Guildford, GB, ²Medanta - The Medicity, Gurugram, IN, ³Kokilaben Dhirubhai Ambani Hospital, Mumbai, IN, ⁴Worcester Polytechnic Institute, Worcester, US, ⁵Datar Cancer Genetics, Nashik, IN

13:15 - 13:15 **95P - ABCB7 is a gatekeeper of both programmed cell death, apoptotic and non-apoptotic cell death**

J.Y. Kim, H. Kim, Korea University, Seoul, KR

13:15 - 13:15 **96P - Assessments of cancer-free lymph nodes for the prediction of disease progression**

A. Grigoriadis¹, N. Kurian², S. Ankathi¹, T. Hardiman¹, N. Woodman¹, J. Owens¹, S. Paharia², S. Meena², A. Coolen¹, S. Rane³, C. Gillett¹, S. Pinder¹, A. Sethi², ¹King's College London Guy's Hospital, London, GB, ²IIT, Bombay, IN, ³Tata Memorial Centre, Mumbai, IN

13:15 - 13:15 **97P - Community-driven development of a modified progression-free survival ratio for precision oncology trials**

A. Mock¹, C. Heilig², S. Kreutzfeldt³, D. Hübschmann⁴, C. Heinrich⁵, E. Schröck⁶, B. Brors³, A. Stenzinger⁷, D. Jäger⁴, R. Schlenk⁴, H. Glimm⁸, S. Fröhling⁹, P. Horak¹⁰, ¹NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, ²University of Heidelberg, Heidelberg, DE, ³German Cancer Research Center, Heidelberg, DE, ⁴NCT Heidelberg, Heidelberg, DE, ⁵NCT Dresden, Dresden, DE, ⁶Faculty of Medicine Carl Gustav Carus, Dresden, DE, ⁷University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE, ⁸National Center for Tumor Diseases, Partner site Dresden (NCT), Dresden, DE, ⁹German Cancer Research Center (DKFZ), Heidelberg, DE, ¹⁰Donauspital im SMZ-Ost, Vienna, AT

13:15 - 13:15 **98P - Comparison of whole exome sequencing and FoundationOne Heme sequencing panel as tools for precision oncology in paediatric patients with difficult-to-treat solid tumours**

H. Nosková¹, S. Adamcová², D. Knoflíčková², K. Pál², A. Grioni², T. Horňáková³, T. Merta¹, P. Múdry¹, Z. Pavelka¹, K. Vejmělková¹, J. Štěrba¹, O. Slabý², ¹University Hospital Brno-Children's Medical Centre, Brno, CZ, ²CEITEC Masaryk University, Brno, CZ, ³Roche s.r.o., Praha, CZ

13:15 - 13:15 **99P - Likelihood of targeted therapy recommendations for advanced solid tumours**

H. Taghizadeh¹, G. Prager², L. Müllauer³, R. Mader⁴, ¹Universitätsklinik für Innere Medizin III, Wien, AT, ²Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, ³Medical University of Vienna, Vienna, AT, ⁴Medical University of Vienna, Vienna, AT

13:15 - 13:15 **100P - Concordance between tissue analysis (TA) and liquid biopsy (LB) for RAS/BRAF and the optimization of its clinical application in such a heterogeneous tumour**

I. Grilo¹, R. Leite², P. Gago¹, S. Duarte¹, A. Teira¹, T. Sarmento¹, M. Sousa¹, ¹Centro Hospitalar Tras-os-Montes e Alto Douro, E.P.E., Vila Real, PT, ²CHTMAD, Vila Real, PT

13:15 - 13:15 **101P - Clinical application of routine comprehensive tumour molecular profiling in the management of cancer patients**

V. Mileyko¹, E. Veselovsky², E. Rozhavskaya², E. Ignatova³, A. Kovtun², M. Sharova², M. Ivanov⁴, ¹Atlas Oncodiagnostics, LLS, Moscow, RU, ²Atlas OncoDiagnostics ltd., Moscow, RU, ³FSB-N. N. Blokhin Russian Cancer Research Center, Moscow, RU, ⁴Moscow Institute of Physics and Technology, Dolgoprudny, RU

13:15 - 13:15 **102P - Encyclopedic tumour analysis (ETA) guided combination regimens of hormone receptor antagonists with other systemic agents for treatment of refractory cancers**

A. Vaid¹, T. Crook², A. Ranade³, S. Limaye⁴, D. Patil⁵, D. Akolkar⁵, V. Datta⁵, R. Page⁶, S. Schuster⁷, C. Sims⁵, R. Patil⁵, A. Srinivasan⁵, S. Apurwa⁵, R. Datar⁵, ¹Medanta - The Medicity, Gurugram, IN, ²Royal Surrey County Hospital, Guildford, GB, ³Avinash Cancer Clinic, Pune, IN, ⁴Kokilaben Dhirubhai Ambani Hospital, Mumbai, IN, ⁵Datar Cancer Genetics, Nashik, IN, ⁶Worcester Polytechnic Institute, Worcester, US, ⁷Datar Cancer Genetics Europe GmbH, Bayreuth, DE

13:15 - 13:15 **103P - Comparative study of RT-qPCR- and NGS- based platforms for circulating human microRNA biomarker detection**

C. Gargiuli, M. Dugo, L. De Cecco, M. Iannò, A. Mariancini, E. Marchesi, E. Mancinelli, A. Micali, M. Boeri, G. Sozzi, M. Sensi, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

13:15 - 13:15 **104P - AI oncology algorithm-based prioritisation of EGFR inhibitors in case of rare EGFR mutations**

B. Vodicska¹, E. Kispéter¹, M. Vidermann¹, R. Doczi¹, D. Tihanyi¹, C. Hegedus¹, P.

Filotas¹, L. Urban², I. Petak¹, ¹Oncompass Medicine Hungary Kft., Budapest, HU,
²Matrahaza University and Teaching Hospital, Matrahaza, HU

13:15 - 13:15 **105P - Anti-osteolytic use to prevent skeletal related events in solid tumour bone metastases**

C. Woodard¹, D. Henry², ¹Royal College of Surgeons in Ireland, Dublin, IE, ²University of Pennsylvania - Pennsylvania Hospital, Philadelphia, US

13:15 - 13:15 **106P - A 19-year retrospective analysis of venous thromboembolism trends in chemotherapy-induced anemia: Red blood cell transfusion versus erythrocyte stimulating agent administration**

E. Bryer¹, M. Kallan², T.-S. Chiu², K. Scheuba², D. Henry³, ¹Pennsylvania Hospital, Philadelphia, US, ²University of Pennsylvania, Philadelphia, US, ³University of Pennsylvania - Pennsylvania Hospital, Philadelphia, US

13:15 - 13:15 **107P - RNAi and CRISPR/Cas9-based screens identify mismatch repair genes involved in platinum chemoresistance**

P. Zawadzki, A. Piotrowska, Adam Mickiewicz University - Faculty of Physics, Poznan, PL

13:15 - 13:15 **108P - Targeted proximity ligation assays combined with sequencing for robust detection of translocations in FFPE samples**

H. Feitsma¹, M. Yilmaz¹, J. Swennenhuis¹, A. Rakszewska¹, K. Hajo¹, E. Splinter¹, M. Simonis¹, M. Van Min¹, T. Van Wezel², ¹Cergentis, Utrecht, NL, ²LUMC, Leiden, NL

13:15 - 13:15 **109P - Association of rs363293 single nucleotide polymorphism in promoter region of miRNA-143/145 with susceptibility to colorectal cancer and with patients' outcome**

G. Mihaylova¹, D. Ivanova¹, R. Manev¹, O. Tasinov¹, N. Nazifova-Tasinova¹, V. Petrova², D. Petkova- Nelova², Z. Mihaylova², N. Conev¹, I. Donev³, M. Radanova¹, ¹Medical University of Varna, Varna, BG, ²Military Medical Academy, Sofia, BG, ³Hospital Nadezhda, Sofia, BG

13:15 - 13:15 **110P - Pan-cancer analysis for oncogenes and mechanisms of their upregulation**

A. Dmitriev¹, G. Krasnov², N. Melnikova², E. Pushkova², R. Novakovskiy², A. Kudryavtseva², A. Beniaminov², ¹Engelhardt Institute of Molecular Biology Russian Academy of Sciences, Moscow, RU, ²Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, RU

13:15 - 13:15 **111P - mTOR inhibitors in combination regimens guided by encyclopedic tumour analysis show superior outcomes compared to monotherapy in refractory cancers**

T. Crook¹, A. Vaid², S. Limaye³, R. Page⁴, D. Patil⁵, D. Akolkar⁵, V. Datta⁵, A. Ghaisas⁵, R. Patil⁵, H. Singh⁵, A. Srinivasan⁵, S. Apurwa⁵, R. Datar⁵, ¹Royal Surrey County Hospital, Guildford, GB, ²Medanta - The Medicity, Gurugram, IN, ³Kokilaben Dhirubhai Ambani Hospital, Mumbai, IN, ⁴Worcester Polytechnic Institute, Worcester, US, ⁵Datar Cancer Genetics, Nashik, IN

13:15 - 13:15

Last update: 08-11-2019 11:51:30am

Programme

112P - A Bayesian framework to quantify survival uncertainty

H. Loya¹, D. Anand¹, P. Poduval¹, N. Kumar², A. Sethi², ¹Indian Institute of Technology Bombay, Mumbai, IN, ²University of Illinois at Chicago, Chicago, US

13:15 - 13:15

113P - Copy number variations in critical cell-signalling genes with potential targeted therapeutic application

E. Nikolova, V. Mitev, A. Todorova, Medical University Sofia, Sofia, BG

13:15 - 13:15

114P - Signal: The home page of mutational signatures

S. Shooter, J. Czarnecki, S. Nik-Zainal, University of Cambridge - MRC Cancer Unit, Cambridge, GB

13:15 - 13:15

115P - Detection of actionable variants in various cancer types reveals value of whole-genome sequencing over in-silico whole-exome and hotspot panel sequencing

K. Ramarao-Milne¹, A.-M. Patch², K. Nones², R. Koufariotis², F. Newell², V. Addala¹, O. Kondrashova², P. Mukhopadhyay², S. Kazakoff², V. Lakis², O. Holmes², C. Leonard², S. Wood², C. Xu², J. Pearson², G. Hollway², N. Waddell², ¹University of Queensland, Brisbane, AU, ²QIMR Berghofer Medical Research Institute, Brisbane, AU

13:15 - 13:15

116P - Large scale functional characterization of mutations and their susceptibility to targeted therapy

Z. Barbash, G. Tarcic, D. Haham, L. Hafzadi, R. Zipor, S. Barth, A. Aizenman, NovellusDx, Jerusalem, IL

13:15 - 13:15

117P - Correlation of MRI derived parameters and SUV uptake obtained from FDG- PET-CT with human papillomavirus status in oropharyngeal squamous cell carcinomas

S. Goyal¹, V.P.B. Koyyala², A. Jajodia², A. Chaturvedi³, M. Gairola³, A. Rao³, M. Sharma², S. Pasricha³, P. Alhawat³, V. Mahawar³, B. Amrith³, R. Tripathi³, ¹Rajiv Gandhi Cancer Institute & Research Center, New Delhi, IN, ²Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN, ³Rajiv Gandhi Cancer Institute and Research Centre, NEW DELHI, IN

13:15 - 13:15

119P - Role of immune checkpoint inhibitors in bone sarcomas and future aspects

A. Mishra¹, S. Medhashri², Y. Mishra³, ¹Gandhi Medical College, Bhopal, IN, ²BURKATULLAH UNIVERISTY, Gurgaon, IN, ³PCMS, Bhopal, IN

13:15 - 13:15

120TiP - EORTC SPECTA-AYA: A molecular profiling platform for adolescents and young adults with cancer in Europe

T. De Rojas¹, B. Kasper², W. Van Der Graaf³, S. Pfister⁴, F. Bielle⁵, T. Ribalta⁶, P. Shenjere⁷, M. Preusser⁸, S. Fröhling⁹, M. Morfouace¹, M. McCabe¹⁰, ¹EORTC - European Organisation for Research and Treatment of Cancer, Brussels, BE, ²Mannheim University Medical Center, Mannheim, DE, ³Netherlands Cancer Institute van Leeuwenhoek, Amsterdam, NL, ⁴German Cancer Research Center (DKFZ), Heidelberg, DE, ⁵La Pitié-Salpêtrière Hospital, Paris, FR, ⁶Hospital Sant Joan de Deu, Barcelona, ES, ⁷The Christie

NHS Foundation Trust, Manchester, GB, ⁸Medical University of Vienna, Vienna, AT, ⁹NCT Heidelberg, Heidelberg, DE, ¹⁰University of Manchester, Manchester, GB

| | | |
|--|---|---------------------|
| 14:00 - 15:30 | Transforming imaging into predictors | Fleming room |
| Moderation: F. André, Breast Cancer Unit, Medical Oncology Department, Gustave Roussy - Cancer Campus, Villejuif, FR | | |

14:00 - 14:00 **Session DOI**

14:00 - 14:20 **Artificial Intelligence (AI) in radiology**
H. Aerts, Harvard Medical School, Boston, US

14:20 - 14:40 **Radiomics to predict sensitivity to immunotherapeutics**
E. Deutsch, Institut Gustave Roussy, Villejuif, FR

14:40 - 15:00 **Digital multiplexed pathology**
I. Wistuba, The University of Texas MD Anderson Cancer Center, Houston, US

15:00 - 15:20 **Computational tools to interpret multiplexed pathology**
L. Keren, Stanford University, Stanford, US

15:20 - 15:30 **Q&A**

| | | |
|---|---------------------------------------|---------------------|
| 15:30 - 16:15 | Gordon Peters Memorial Keynote | Fleming room |
| Moderation: C. Swanton, Translational Cancer Therapeutics Department, The Francis Crick Institute, London, GB | | |

15:30 - 15:30 **Session DOI**

15:30 - 16:15 **Myc and microenvironment**
G. Evan, University of Cambridge, Cambridge, GB

| | | |
|----------------------|---------------------|---------------------|
| 16:15 - 16:40 | Coffee break | Britten room |
|----------------------|---------------------|---------------------|

16:40 - 18:00 Immuno - (Prediction of therapy and response)

Fleming room

16:40 - 16:40 **Session DOI**

16:40 - 17:00 **Revealing the role of nonsense mediated decay in anti-tumour immunogenicity**

K. Litchfield, The Francis Crick Institute, London, GB

17:00 - 17:20 **Predicting antigen presentation**

M. Bassani-Sternberg, Ludwig Cancer Center of the University of Lausanne - CHUV, Lausanne, CH

17:20 - 17:40 **Combining antigen presentation and T cell recognition to reveal immune responses**

Y. Samuels, Weizmann Institute of Science, Rehovot, IL

17:40 - 18:00 **Unbiased high throughput identification of tumour-reactive TCRs from TIL**

W. Schepers, The Netherlands Cancer Institute, Amsterdam, NL

09.11.2019

| | |
|---|---------------------|
| 08:30 - 10:00 Single cell analysis / single cell sequencing | Fleming room |
| Moderation: J. Haanen, Medical Oncology Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL | |

08:30 - 08:30 **Session DOI**

08:30 - 08:50 **Subclonal heterogeneity and behaviour in TNBC**

L. Ellisen, Massachusetts General Hospital, Boston, US

08:50 - 09:10 **Paracrine signalling controls IFNa production by plasmacytoid DC**

J. De Vries, Radboud University Medical Centre Nijmegen, Nijmegen, NL

09:10 - 09:30 **Clonal diversity of the T cell repertoire in lung cancer**

S. Quezada, University College London, London, GB

09:30 - 09:50 **TET2 and DNA methylation in hematopoietic transformation**

O. Bernard, Gustave Roussy - Cancer Campus, Villejuif, FR

09:50 - 10:00 **5O - Using single cell data to validate the cellular origins of a clonal expression biomarker in lung cancer**

D. Biswas¹, N. Birkbak², N. Mcgranahan³, C. Swanton⁴, ¹UCL Cancer Institute/Paul O'Gorman Building, London, GB, ²Aarhus University, Aarhus, DK, ³Cancer Research UK, London, GB, ⁴The Francis Crick Institute, London, GB

10:00 - 10:30 Coffee break

Britten room

10:30 - 12:00 Germline susceptibility

Fleming room

Moderation: C. Turnbull, The Institute Of Cancer Research, The Institute of Cancer Research (ICR), London, GB

10:30 - 10:30 **Session DOI**

10:30 - 10:50 **Interpretation of germline variation in cancer susceptibility genes: Pitfalls and challenges**

C. Turnbull, The Institute of Cancer Research (ICR), London, GB

10:50 - 11:10 **Emerging management paradigms in syndromes of high penetrance susceptibility: TP53 as an exemplar case**

H. Hanson, St George's Hospital NHS Trust, London, GB

11:10 - 11:30 **Polygenic genomic profiling: Cancer risk prediction in the population - Opportunity versus hype**

P. Pharoah, University of Cambridge-Public Health and Primary Care, Cambridge, GB

11:30 - 11:50 **Integration of analyses of the germline and the tumour for optimal patient management**

A. George, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

11:50 - 12:00 **Q&A**

| | | |
|---|--|---------------------|
| 12:05 - 12:50 | Industry satellite - Roche: Novel approaches in personalised healthcare | Fleming room |
| Moderation: J. Sicklick, Surgery, University of California San Diego - UCSD, La Jolla, US | | |

12:05 - 12:19 **Personalised therapy based on comprehensive genomic profiling**
J. Sicklick, University of California San Diego - UCSD, La Jolla, US

12:19 - 12:28 **Interactive patient case focused on comprehensive genomic profiling resulting in treatment with combination therapies**
J. Sicklick, University of California San Diego - UCSD, La Jolla, US

12:28 - 12:42 **Use of liquid biopsy based genomic profiling**
D. Rothwell, Cancer Research UK Manchester Institute, Manchester, GB

12:42 - 12:50 **Interactive patient case focused on comprehensive genomic profiling via liquid biopsy**
D. Rothwell, Cancer Research UK Manchester Institute, Manchester, GB

| | | |
|--|-------------------------------------|---------------------|
| 12:50 - 13:30 | Lunch | Britten room |
| 13:30 - 14:15 | Targeting cancer neoantigens | Fleming room |
| Moderation: C. Swanton ¹ , J. Haanen ² , ¹ Translational Cancer Therapeutics Department, The Francis Crick Institute, London, GB, ² Medical Oncology Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL | | |

13:30 - 13:30 **Session DOI**

13:30 - 14:15 **Targeting cancer neoantigens**
Ö. Türeci, BioNTech AG, Mainz, DE

14:15 - 15:30 Biomarkers and checkpoint inhibitor

Fleming room

Moderation: S. Turajlic¹, F. André², ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²Breast Cancer Unit, Medical Oncology Department, Gustave Roussy - Cancer Campus, Villejuif, FR

14:15 - 14:15 Session DOI

14:15 - 14:35 Predictive biomarkers for the efficacy of IO: which biomarkers to use for daily use?

J. Haanen, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

14:35 - 14:55 Predictive biomarkers for the efficacy of IO: What's in the pipeline

D. Thommen, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NL

14:55 - 15:10 Discussion

15:10 - 15:20 6O - Comprehensive genomic profiling and outcomes among metastatic melanoma patients (pts) treated with first-line cancer immunotherapy (CIT) in a real-world setting

N. Sadetsky¹, P. Lambert², C. Julian², J. Chen², Y. Yan¹, ¹Genentech Inc. - Roche - USA, South San Francisco, US, ²Genentech Inc., South San Francisco, US

15:20 - 15:30 7O - Contrasting the drivers of response to immunotherapy across solid tumour types: Results from analysis of&&

K. Litchfield¹, C. Swanton¹, S. Turajlic², N. Mcgranahan³, S. Quezada⁴, ¹The Francis Crick Institute, London, GB, ²Royal Marsden Hospital NHS Foundation Trust, London, GB, ³Cancer Research UK, London, GB, ⁴University College London, London, GB

15:30 - 16:00 Coffee break

Britten room

16:00 - 17:30 Targeting the PI3K pathway in human epithelial malignancies' Fleming room

Moderation: C. Caldas, Oncology, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB

16:00 - 16:00 **Session DOI**

16:00 - 16:20 **Assessing the PI3K pathway in breast cancer: How best to stratify patients**

C. Caldas, Cambridge University Hospitals NHS Foundation Trust - Addenbrooke's Hospital, Cambridge, GB

16:20 - 16:40 **Direct and indirect anti-cancer effects of PI3K isoforms'**

B. Vanhaesebroeck, UCL - University College London, London, GB

16:40 - 17:00 **Targeting the PI3K pathway: Trials and tribulations**

L. Friedman, Genentech Inc. - Roche - USA, South San Francisco, US

17:00 - 17:20 **Predictive markers of PIK3CA efficacy**

F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

17:20 - 17:30 **8O - Targeting EGFR exon 20 insertions in non-small cell lung cancer by exploiting a dependency on parallel SRC signalling**

S. Vyse¹, N. Chen², J. Oddy¹, P. Harrison¹, A. Le², A. Estrada-Bernal², M. Hermsen³, R. Doebele², P. Huang¹, ¹The Institute of Cancer Research (ICR), London, GB, ²University of Colorado School of Medicine, Aurora, US, ³Hospital Universitario Central de Asturias, Oviedo, ES